Website
News25/Ratings6
News · 26 weeks470%
2025-10-262026-04-19
Mix2490d
- Insider12(50%)
- SEC Filings6(25%)
- Earnings3(13%)
- Other2(8%)
- Leadership1(4%)
Latest news
25 items- PRKORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2026 financial results on Wednesday, May 6, 2026. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international ca
- SECSEC Form DEF 14A filed by KORU Medical Systems Inc.DEF 14A - KORU Medical Systems, Inc. (0000704440) (Filer)
- INSIDERAmendment: SEC Form 4 filed by Manko Joseph M. Jr.4/A - KORU Medical Systems, Inc. (0000704440) (Issuer)
- SECKORU Medical Systems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - KORU Medical Systems, Inc. (0000704440) (Filer)
- INSIDERSEC Form 4 filed by Wholihan Edward4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
- INSIDERSEC Form 4 filed by Cascella Robert4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
- INSIDERSEC Form 4 filed by French Donna4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
- INSIDERSEC Form 4 filed by Matin Shahriar4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
- INSIDERSEC Form 4 filed by Fletcher R John4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
- INSIDERSEC Form 4 filed by Manko Joseph M. Jr.4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
- INSIDERSEC Form 4 filed by Kalbermatten Adam R4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
- INSIDERSEC Form 4 filed by Pazdan Christopher4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
- INSIDERSEC Form 4 filed by Adams Thomas Edward4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
- INSIDERSEC Form 4 filed by Tharby Linda M4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
- SECKORU Medical Systems Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - KORU Medical Systems, Inc. (0000704440) (Filer)
- PRKORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe CompatibilityKORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that its Freedom60® Infusion Pump, including adapter for use with 50 mL prefilled syringes, has achieved certification under the European Union Medical Devices Regulation (EU MDR 2017/745), enabling commercialization across the European Union. The Freedom60 Infusion Pump is designed to support dosing with 50 ml prefilled syringes, while the FreedomEDGE® Infusion System provides a compatible option for 20 mL prefilled sy
- SECSEC Form 10-K filed by KORU Medical Systems Inc.10-K - KORU Medical Systems, Inc. (0000704440) (Filer)
- PRKORU Medical Systems Announces CEO TransitionLinda Tharby to Retire after Five Years of Transformational Leadership; Adam Kalbermatten Appointed CEO, effective July 1, 2026 KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that following five years of service to the Company, Linda Tharby, President and Chief Executive Officer, will retire effective June 30, 2026. The Board of Directors has appointed Adam Kalbermatten, currently Chief Commercial Officer, as President and Chief Executive Officer, effective March 15
- SECKORU Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - KORU Medical Systems, Inc. (0000704440) (Filer)
- PRKORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 GuidanceKORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company also initiated guidance for the full year 2026. Recent Highlights Fourth quarter 2025 net revenues grew 23% to $10.9 million; Full year 2025 net revenues grew 22% to $41.1 million Full year 2025 gross profit grew 20% to $25.6 million with gross margin of 62.3% Full year 2025 net loss of ($2.6) million, a 57% improvement o
- PRKORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report fourth quarter and full year 2025 financial results on Thursday, March 12, 2026. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for
- INSIDERDirector Manko Joseph M. Jr. disposed of 1,520,418 shares and acquired 1,032,347 shares, increasing direct ownership by 56% to 782,547 units (SEC Form 4)4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
- SECKORU Medical Systems Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - KORU Medical Systems, Inc. (0000704440) (Filer)
- PRKORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion SystemKORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company received U.S. Food and Drug Administration (FDA) clearance for use of the KORU Medical FreedomEDGE® infusion system to deliver RYSTIGGO® (rozanolixizumab-noli), a therapy commercialized globally by UCB, Brussels, Belgium (www.ucb.com). The clearance for the FreedomEDGE® label includes indicated administration by a healthcare professional, increasing flexibility and access for patients living with genera
- INSIDERChief Technology Officer Schiller Eric was granted 76,426 shares (SEC Form 4)4 - KORU Medical Systems, Inc. (0000704440) (Issuer)